Trident Lifeline Limited (TLL) Fair Value & Analysis
Healthcare · IN · Market cap ₹3.1B
Fair value as of: Jul 6, 2026
From 14 valuation models · updated today
Share price +8.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹237.90 – ₹322.00 · fair‑value band ₹191.73 – ₹337.88 · the ₹263.95 price screens below the ₹270.30 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Trident Lifeline Limited (TLL) currently trades at ₹263.95, while our model-based Fair Value estimate is ₹270.30 — implying the stock looks roughly 2.4% undervalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Trident Lifeline Limited generated revenue of ₹1.3B at a net margin of 14.8%. Revenue grew 5.1% year over year. It earns a return on equity of 21.8%. Net debt stands at ₹688M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹191.73 (bear case) to ₹337.88 (bull case); at ₹263.95, the current price sits within that range. The share trades about 20% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside — at 2%, TLL screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Trident Lifeline Limited, a pharmaceutical company, engages in the manufacture and marketing of finished dosages in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. It offers pharmaceutical products in the form of tablets, capsules, liquid orals, external preparations, gel, mouthwash, and lotion; and nutraceutical tablets, capsules, liquids, sachets, oral sprays, and effervescent tablets, as well as ice gels, pastes, solutions, suspension, syrup, cream, drypowders, and toothpastes. The company was incorporated in 2014 and is based in Surat, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Trident Lifeline Limited reported revenue of ₹1.3B in FY2026 versus ₹218M in FY2022, a compound +56.0%/yr. Reported net income was ₹190M in FY2026, compounding +48.2%/yr from FY2022.
Is TLL fairly valued? → Check now
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIF | $5.85 | $7.13 | +22% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$17.46 | R$16.13 | -8% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $29.02 | $34.57 | +19% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $40.69 | +37% |
| DaShenLin Pharmaceutical Group 603233 | ¥16.68 | ¥19.21 | +15% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.18 | ¥13.89 | +14% |
| Redcare Pharmacy NV SHPPF | $64.80 | $143.56 | +122% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Trident Lifeline Limited (TLL) undervalued?
What is the fair value of TLL?
What is the quality score of TLL?
What is the revenue of Trident Lifeline Limited (TLL)?
What is the net profit margin of TLL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.